Vascular Dysfunction in Human Obesity Hypertension
Status:
Terminated
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the effects of: 1) blocking sympathetic nerve activity
with a drug called clonidine, and 2) by blocking a kidney protein called renin, and on blood
vessel function and muscle nerve activity in adults who are obese and have high blood
pressure.
The cohort of subjects will consist of 69 healthy young men and women age 18-79 years who are
obese, defined as a body mass index > or = to 30 kg/m2, who have untreated systolic
hypertension (systolic blood pressure > or = to 130 - <180 mmHg- average of at least 3
measurements 2 min apart after 10 min seated resting position). These 69 subjects will then
be randomized to 3 treatment arms: clonidine (0.1 mg/day), hydrochlorothiazide (25 mg/day) or
placebo for 4 weeks in years 1 and 2. All tablets will be encapsulated by to look identical.
Subjects will randomly (1:1:1) receive one of the following combinations in a double-blind,
placebo-controlled design:
1. Oral clonidine (0.1 mg twice/day)
2. Oral hydrochlorothiazide (12.5 mg twice/day)
3. Oral placebo
I
Phase:
Phase 2
Details
Lead Sponsor:
Gary L. Pierce University of Iowa
Collaborators:
American Heart Association National Institutes of Health (NIH)